Amphista Therapeutics

Executive Summary

Amphista Therapeutics is a UK-based biotechnology company founded in 2017, pioneering next-generation targeted protein degradation (TPD) therapeutics through its proprietary Targeted Glues® platform. The company aims to overcome the limitations of first-generation TPD approaches, such as poor drug-like properties and suboptimal degradation efficiency, by developing small molecules that induce proximity between E3 ligases and disease-causing proteins for selective elimination. Amphista focuses on intractable diseases in oncology, immunology, and neuroscience, addressing high unmet medical needs. Headquartered in Cambridge, UK, the company leverages the region's vibrant biopharma ecosystem to advance its pipeline. The company's platform utilizes rational design and screening to identify novel glue degraders with improved pharmacokinetics and bioavailability. Amphista's lead programs target validated oncogenic drivers and immune checkpoints, with potential to expand into neurodegenerative disorders. Preclinical data have demonstrated potent degradation in in vitro and in vivo models, with favorable safety profiles. The company has attracted significant venture capital backing and established academic collaborations. If successful, Amphista's catalytic degraders could offer superior therapeutic options compared to existing modalities like PROTACs, positioning it as a leader in the second wave of TPD. Near-term milestones include IND-enabling studies and potential partnership discussions.

Upcoming Catalysts (preview)

• Q2 2025IND/CTA Filing for Lead Oncology Program60% success
• Q4 2024Series C Funding Round Announcement70% success
• Q1 2025Preclinical Data Presentation at Major Conference80% success